[The effect of mildronate on carnitine-dependent and carnitine-independent ketogenesis in rats].
Mildronate of 3-(2,2,2-trimethylhydrozinium)propionate, a novel anti-ischemic drug, inhibits the biosynthesis of carnitine from Y-butyrobetaine. Continuous administration of mildronate (200, 400 mg/kg for 10 days orally) to rats exerted a marked antiketogenic action on the animals deprived of food for 48 hours. In the fed rats receiving sodium octanoate a course treatment with mildronate elevated to concentration of ketone bodies in blood serum. Selective regulation of carnitine-independent and carnitine-dependent metabolism appears justified for the treatment of such pathological states as ischemic heart disease, diabetes and obesity.
Simkhovich
B Z
BZ
Meĭrena
D V
DV
Khagi
Kh B
KhB
Shutenko
Zh V
ZhV
Molodchina
T N
TN
Kalvin'sh
I Ia
IIa
Lukevits
E Ia
EIa
D020155:3-Hydroxybutyric Acid; D000818:Animals; D002331:Carnitine / Q000037:antagonists & inhibitors* / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005215:Fasting / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006885:Hydroxybutyrates / Q000097:blood; D007657:Ketone Bodies / Q000096:biosynthesis* / Q000097:blood; D008297:Male; D008763:Methylhydrazines / Q000494:pharmacology*; D051381:Rats
D005230:Fatty Acids, Nonesterified; D006885:Hydroxybutyrates; D007657:Ketone Bodies; D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate; D002331:Carnitine; D020155:3-Hydroxybutyric Acid
Vliianie mildronata na karnitinzavisimyĭ i karnitinnezavisimyĭ ketogenez u krys.